Sign in

NCT06885827Recruiting

Vitamin Mix (B6, B9, B12, And Choline) For Glaucoma Patients

Interventional Vitamin Mix Glaucoma Study (IVMGS) - A Prospective, Randomized, Two-Arm, Single-Center Study Protocol in Existing Glaucoma Patients.

Source: ClinicalTrials.gov · Last updated 29 Apr 2025 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

This study aims to determine whether a combination of vitamins (B6, B9, B12, and choline) can help protect the eyes of people with glaucoma and slow vision loss. The study will assess whether these vitamins support retinal cells and maintain or improve their function. Adults aged 18 and older with primary open-angle glaucoma (including normal-tension glaucoma) or pseudoexfoliation glaucoma, and those with mild to moderate glaucoma, may be eligible. Participants must meet specific medical criteria and cannot take additional vitamin supplements during the study. Participants will be randomly assigned to one of two groups: one group will take a daily vitamin supplement (B6, B9, B12, and choline) for one year, along with standard glaucoma care, while the other will continue standard care without extra vitamins. The vitamins used are well tolerated at selected doses, with possible mild side effects such as an upset stomach or tingling sensations. They will visit the clinic five times over 12 months (at the start, and at 3, 6, 9, and 12 months) for routine eye tests, including measuring eye pressure, checking vision and visual fields, taking scans of the eye's nerve layers (OCT), and completing an electroretinogram (ERG) to assess retinal function. Blood samples will also be collected. If the vitamins are effective, this could provide an additional strategy alongside current eye pressure lowering treatments to reduce vision loss.

Status (registry)
Recruiting
Study type
Interventional
Enrollment
80 (estimated)
First submitted
10 Mar 2025
Start date
31 Mar 2025
Primary completion date
31 Mar 2027
Lead sponsor
Karolinska Institutet
Diseases
Glaucoma
NCT number
NCT06885827

What you commit to

  • Study type: Interventional
  • Planned participants: 80
  • From 31 Mar 2025 to the primary completion date, 31 Mar 2027
  • 2 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Previous eye surgery, except for uncomplicated cataract surgery

Other illness

  • Any disease affecting retinal function
  • Neurological or other non-glaucomatous conditions that may affect the visual field
  • Known allergy or intolerance to B-vitamins
  • Any disease or condition likely to prevent long-term follow-up
  • Cancer diagnosis within the last 5 years (except treated squamous cell carcinoma)
  • History of liver disease or stomach ulcers

Other

  • Patients who meet any of the following criteria will be excluded from participation in the study:
  • Visual field damage worse than -16dB in the study eye(s)
  • Eye pressure greater than 35 mmHg in study eye(s) on either of two measurement occasions or a mean pressure of 30 mmHg over two occasions
  • Inability to perform visual field examination
  • Unwillingness to stop any intake of multivitamins or B vitamin substances
  • Pregnant or breastfeeding women
  • Women of childbearing potential who do not use reliable contraception
  • Inability to understand and speak Swedish or English

Who the study is looking for

  • Patients with the following characteristics will be eligible for inclusion in the trial:
  • 18 years or older at the time of inclusion
  • Diagnosis of Primary Open-Angle Glaucoma (POAG), Normal Tension-Glaucoma (NTG) or Pseudoexfoliation Glaucoma (PEXG) in one or both eyes diagnosticed by an ophthalmologist.
  • Best corrected Snellen VA of 0.3 or better in the study eye(s)
  • Two or more reliable VF tests with less than 15% false positives

Criteria the registry did not label

  • Eligibility Criteria

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (2)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
Karolinska institutet, The Division of Eye and vision.
Coordinator of this site? Confirm its status
StockholmSwedenNot yet recruiting
St Eriks Ögonsjukhus
Coordinator of this site? Confirm its status
StockholmSwedenRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.